WallStSmart

Evommune, Inc. (EVMN)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Evommune, Inc. generates 1248% more annual revenue ($10.00M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. EVMN earns a higher WallStSmart Score of 27/100 (F).

EVMN

Avoid

27

out of 100

Grade: F

Growth: 6.0Profit: 2.5Value: 5.0Quality: 9.0
Piotroski: 4/9Altman Z: 4.58

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EVMN3 strengths · Avg: 9.3/10
Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.5810/10

Safe zone — low bankruptcy risk

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

EVMN4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$717.49M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : EVMN

The strongest argument for EVMN centers on Debt/Equity, Altman Z-Score, Price/Book.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : EVMN

The primary concerns for EVMN are Revenue Growth, EPS Growth, Market Cap.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

EVMN is growing revenue faster at 0.0% — sustainability is the question.

EVMN generates stronger free cash flow (-28M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

EVMN scores higher overall (27/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Evommune, Inc.

HEALTHCARE · BIOTECHNOLOGY · USA

Evommune, Inc. is a forward-thinking biotechnology firm dedicated to advancing innovative therapeutics for immunological disorders, addressing critical unmet medical needs. The company boasts a promising pipeline and utilizes state-of-the-art research methodologies to optimize immune response and improve patient outcomes. It aims to establish itself as a leader in the dynamic immunotherapy landscape through rigorous scientific practices and strategic collaborations. As Evommune advances its clinical trials, it seeks to offer groundbreaking solutions that may redefine care standards in the field of immunology, ultimately enhancing the quality of life for patients.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?